CLTR COULTER PHARMACEUTICAL Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTR COULTER PHARMACEUTICAL

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (105)	8/15/1998 9:12:00 AM
From: PDavid	Read Replies (1) of 666

Rick Harmon-just a quick response to your check on the TCLN CEO While the background check that you did produced a question as to whether Bymaster played a role in hurting xytronix, I can state that he did not. The events that caused the downward spiral preceded his tenure as CEO, though he was with the company. As CEO, he transformed the company into a cancer therapeutics company (from whatever they were doing in the dental field), which eventually led to the name change. In reality, he saved the company, ushered in new financing and developed increased credibility with the public (which was desperately needed after the debacle). He also developed a fine relationship with the FDA. I apologize in advance for this post, as I am a tcln shareholder and have no intentions on offending anybody over here. I just saw your post and wanted to clarify some things. I met Bymaster in a recent shareholders luncheon in New York. He was questioned about his association with Xytronix and addressed the very concern that you raised. Phil

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next